These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. Schnell S, Young JW, Houghton AN, Sadelain M. J Immunol; 2000 Feb 01; 164(3):1243-50. PubMed ID: 10640737 [Abstract] [Full Text] [Related]
4. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Rowe HM, Lopes L, Ikeda Y, Bailey R, Barde I, Zenke M, Chain BM, Collins MK. Mol Ther; 2006 Feb 01; 13(2):310-9. PubMed ID: 16275163 [Abstract] [Full Text] [Related]
9. Similar immune responses and antitumor effects of murine dendritic cells loaded with either exogenous or endogenous-synthesized protein. Lacave R, Masurier C, Guigon M, Lemoine FM, Klatzmann D, Colombo BM. Int J Oncol; 2003 Dec 15; 23(6):1747-53. PubMed ID: 14612950 [Abstract] [Full Text] [Related]
10. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. He T, Tang C, Xu S, Moyana T, Xiang J. Cell Mol Immunol; 2007 Apr 15; 4(2):105-11. PubMed ID: 17484804 [Abstract] [Full Text] [Related]
11. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J. J Immunol; 1998 Dec 01; 161(11):6238-44. PubMed ID: 9834111 [Abstract] [Full Text] [Related]
12. Immunization of retrovirus-transfected dendritic cells induces specific cytotoxic T lymphocytes for two distinct malarial peptides presented by Kd molecule. Hetttihewa LM. Int Immunopharmacol; 2003 Oct 01; 3(10-11):1401-11. PubMed ID: 12946436 [Abstract] [Full Text] [Related]
13. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV. J Immunol; 1999 Jun 01; 162(11):6426-32. PubMed ID: 10352256 [Abstract] [Full Text] [Related]
14. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J, Saffold S, Cao X, Krauss J, Chen W. J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528 [Abstract] [Full Text] [Related]
15. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. Lee JM, Mahtabifard A, Yamada R, Crystal RG, Korst RJ. Clin Cancer Res; 2002 Nov 15; 8(11):3561-9. PubMed ID: 12429647 [Abstract] [Full Text] [Related]
17. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity. Mitsui H, Okamoto T, Kanzaki M, Inozume T, Shibagaki N, Shimada S. Br J Dermatol; 2010 Jan 15; 162(1):29-41. PubMed ID: 19863514 [Abstract] [Full Text] [Related]
18. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design. Herrera OB, Brett S, Lechler RI. Vaccine; 2002 Dec 13; 21(3-4):231-42. PubMed ID: 12450698 [Abstract] [Full Text] [Related]
19. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation. Krasteva M, Kehren J, Horand F, Akiba H, Choquet G, Ducluzeau MT, Tédone R, Garrigue JL, Kaiserlian D, Nicolas JF. J Immunol; 1998 Feb 01; 160(3):1181-90. PubMed ID: 9570532 [Abstract] [Full Text] [Related]